The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming

Autor: Dehua Tang, Yida Pan, Lixing Zhou, Chengfei Jiang, Lei Xu, Robert G. Dorfman, Mingming Zhang, Yuyao Yin, Xiaoping Zou, Lei Wang, Jian-lin Wu, Yuming Wang
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Cancer Research
Original article
Mice
Nude

Apoptosis
Oxidative phosphorylation
Biology
medicine.disease_cause
SIRT2
lcsh:RC254-282
Oxidative Phosphorylation
Serine
Cholangiocarcinoma
Proto-Oncogene Proteins c-myc
03 medical and health sciences
Mice
0302 clinical medicine
Sirtuin 2
Cell Movement
medicine
Tumor Cells
Cultured

Animals
Humans
Pyruvate Dehydrogenase (Lipoamide)
Cell Proliferation
Regulation of gene expression
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cellular Reprogramming
Prognosis
Warburg effect
Xenograft Model Antitumor Assays
Mitochondria
Gene Expression Regulation
Neoplastic

Oxidative Stress
030104 developmental biology
Glucose
Bile Duct Neoplasms
030220 oncology & carcinogenesis
Cancer research
Female
Histone deacetylase
Oxidative stress
Zdroj: Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 5, Pp 429-441 (2019)
ISSN: 1476-5586
1522-8002
Popis: Cholangiocarcinoma (CCA) is a malignant cancer with an unknown etiology and an unfavorable prognosis. Most patients are diagnosed at an advanced stage, thus making it essential to find novel curative targets for CCA. Metabolic reprogramming of the tumor cells includes metabolic abnormalities in glucose (known as the Warburg effect) and other substances such as amino acids and fats. Metabolic reprogramming produces anti-oxidant substances, reduces tumor oxidative stress, and finally promotes the proliferation of tumors. There is increasing evidence to imply that SIRT2, a histone deacetylase, and its downstream target cMYC, play metabolic regulatory roles in tumor cells. However, the role of the SIRT2/cMYC pathway in CCA is unclear. To assess the metabolic reprogramming function of the SIRT2/cMYC pathway in CCA and to determine the downstream targets as well as evaluate the therapeutic effect, the CCA RNA-Seq data were downloaded from the TCGA database. Differentially expressed genes were confirmed and KEGG pathway enrichment analysis was performed. Overall, 48 paired CCA samples were collected and subjected to immunohistochemical detection, and the clinical characteristics of participants were summarized. The CCA cells were suppressed or overexpressed with different downstream targets of SIRT2 and then subjected to apoptosis, immunoblotting, seahorse, and metabolites tracing analysis. In vivo experiments were also performed. We found that the SIRT2/cMYC pathway contributed to the proliferation of CCA cells and confirmed that the downstream target is PHDA1 and the serine synthesis pathway. The up-regulated SIRT2 and cMYC levels resulted in low levels of mitochondrial oxidative phosphorylation and increased conversion of glucose to serine and led to poor patient survival. The highly active SIRT2/cMYC pathway up-regulated the serine synthesis pathway pyruvate and increased antioxidant production, thus consequently protecting the CCA cells from oxidative stress-induced apoptosis. Our data revealed that the SIRT2/cMYC pathway plays a critical role in transforming glucose oxidative metabolism to serine anabolic metabolism, thus providing antioxidants for stress resistance. SIRT2/cMYC-induced metabolic reprogramming may represent a new therapeutic target for treating CCA.
Databáze: OpenAIRE